VIGL - Vigil Neuro rises as dosing starts in Phase 1 trial for Alzheimer's drug
2023-10-17 13:07:47 ET
More on Vigil Neuroscience
- Vigil Neuroscience: Interesting Early Data, Wait For Phase 2
- Vigil Neuroscience study for Alzheimer's drug to proceed with FDA restrictions
- Seeking Alpha’s Quant Rating on Vigil Neuroscience
- Historical earnings data for Vigil Neuroscience
- Financial information for Vigil Neuroscience
For further details see:
Vigil Neuro rises as dosing starts in Phase 1 trial for Alzheimer’s drug